MX336359B - Composiciones farmaceuticas y metodos teraputicos que emplean una combinacion de un compuesto complejo de manganeso y una forma compleja no de manganeso del compuesto. - Google Patents
Composiciones farmaceuticas y metodos teraputicos que emplean una combinacion de un compuesto complejo de manganeso y una forma compleja no de manganeso del compuesto.Info
- Publication number
- MX336359B MX336359B MX2012000303A MX2012000303A MX336359B MX 336359 B MX336359 B MX 336359B MX 2012000303 A MX2012000303 A MX 2012000303A MX 2012000303 A MX2012000303 A MX 2012000303A MX 336359 B MX336359 B MX 336359B
- Authority
- MX
- Mexico
- Prior art keywords
- manganese complex
- compound
- combination
- pharmaceutical compositions
- therapeutic methods
- Prior art date
Links
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 title abstract 4
- 229910052748 manganese Inorganic materials 0.000 title abstract 4
- 239000011572 manganese Substances 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 230000001575 pathological effect Effects 0.000 abstract 3
- 239000000969 carrier Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Inorganic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Una composición farmacéutica para el tratamiento de una condición patológica en un paciente comprende, como un primer componente, un complejo de manganeso de la Fórmula (I), y, como un segundo componente, un compuesto complejo no de manganeso de la fórmula (I), opcionalmente junto con uno o más portadores y/o excipientes fisiológicamente aceptables, en donde X, R, R, R y R son como se definen en la presente. Métodos para el tratamiento de una condición patológica en un paciente, por ejemplo, una condición patológica causada por la presencia de radicales libres derivados de oxígeno, comprende administrar al paciente el primer componente y el segundo componente.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22320409P | 2009-07-06 | 2009-07-06 | |
| US30634810P | 2010-02-19 | 2010-02-19 | |
| PCT/IB2010/053097 WO2011004325A1 (en) | 2009-07-06 | 2010-07-06 | Pharmaceutical compositions and therapeutic methods employing a combination of a manganese complex compound and a non-manganese complex form of the compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2012000303A MX2012000303A (es) | 2012-06-01 |
| MX336359B true MX336359B (es) | 2016-01-15 |
Family
ID=42734866
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012000303A MX336359B (es) | 2009-07-06 | 2010-07-06 | Composiciones farmaceuticas y metodos teraputicos que emplean una combinacion de un compuesto complejo de manganeso y una forma compleja no de manganeso del compuesto. |
| MX2015013425A MX355388B (es) | 2009-07-06 | 2010-07-06 | Composiciones farmaceuticas y metodos terapeuticos que emplean una combinacion de un compuesto complejo de manganeso y una forma compleja no de manganeso del compuesto. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015013425A MX355388B (es) | 2009-07-06 | 2010-07-06 | Composiciones farmaceuticas y metodos terapeuticos que emplean una combinacion de un compuesto complejo de manganeso y una forma compleja no de manganeso del compuesto. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10688087B2 (es) |
| EP (1) | EP2451457B1 (es) |
| JP (2) | JP5868852B2 (es) |
| KR (2) | KR101785600B1 (es) |
| CN (2) | CN105688215A (es) |
| AU (1) | AU2010269849B2 (es) |
| BR (1) | BR112012000262A2 (es) |
| CA (1) | CA2767339C (es) |
| ES (1) | ES2665305T3 (es) |
| IL (1) | IL217143A (es) |
| MX (2) | MX336359B (es) |
| RU (1) | RU2563825C2 (es) |
| WO (1) | WO2011004325A1 (es) |
| ZA (1) | ZA201200092B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX336359B (es) * | 2009-07-06 | 2016-01-15 | Pledpharma Ab | Composiciones farmaceuticas y metodos teraputicos que emplean una combinacion de un compuesto complejo de manganeso y una forma compleja no de manganeso del compuesto. |
| IN2014MN01495A (es) * | 2012-01-05 | 2015-04-17 | Pledpharma Ab | |
| JP6133250B2 (ja) | 2014-09-18 | 2017-05-24 | 本田技研工業株式会社 | 繊維強化樹脂成形品の成形方法及びその装置 |
| EP3402475B1 (en) | 2016-01-11 | 2021-10-20 | Egetis Therapeutics AB | Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions |
| JP7065866B2 (ja) * | 2016-11-14 | 2022-05-12 | カールソン－タナー インベスト エーエス | 化学療法で誘発されたｐｓｎを防止および処置するための非遷移金属配位ジピリドキシル化合物の使用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9613182D0 (en) | 1996-06-24 | 1996-08-28 | Nycomed Imaging As | Method |
| EP1060174B1 (en) | 1997-12-23 | 2004-09-22 | Amersham Health AS | Nitric oxide releasing chelating agents and their therapeutic use |
| GB9727224D0 (en) | 1997-12-23 | 1998-02-25 | Nycomed Imaging As | Method |
| FR2823977B1 (fr) * | 2001-04-26 | 2006-12-01 | Univ Rene Descartes | Utilisation du mangafodipir dans le traitement des effets d'un stress oxydatif |
| US20070148154A1 (en) | 2004-12-17 | 2007-06-28 | Universite Rene Descartes (Paris V) | Use of superoxide dismutase mimetics and reductase gultatione in the form of anticancer drugs |
| CA2708113C (en) * | 2007-12-14 | 2017-08-22 | Pledpharma Ab | Compounds for use in the treatment of cancer |
| MX336359B (es) * | 2009-07-06 | 2016-01-15 | Pledpharma Ab | Composiciones farmaceuticas y metodos teraputicos que emplean una combinacion de un compuesto complejo de manganeso y una forma compleja no de manganeso del compuesto. |
-
2010
- 2010-07-06 MX MX2012000303A patent/MX336359B/es unknown
- 2010-07-06 KR KR1020127003035A patent/KR101785600B1/ko active Active
- 2010-07-06 US US13/379,468 patent/US10688087B2/en active Active
- 2010-07-06 ES ES10740006.1T patent/ES2665305T3/es active Active
- 2010-07-06 BR BR112012000262A patent/BR112012000262A2/pt active IP Right Grant
- 2010-07-06 MX MX2015013425A patent/MX355388B/es unknown
- 2010-07-06 EP EP10740006.1A patent/EP2451457B1/en active Active
- 2010-07-06 CA CA2767339A patent/CA2767339C/en active Active
- 2010-07-06 RU RU2012103889/15A patent/RU2563825C2/ru active
- 2010-07-06 KR KR1020177027735A patent/KR101939207B1/ko active Active
- 2010-07-06 WO PCT/IB2010/053097 patent/WO2011004325A1/en not_active Ceased
- 2010-07-06 CN CN201610030809.8A patent/CN105688215A/zh active Pending
- 2010-07-06 AU AU2010269849A patent/AU2010269849B2/en not_active Ceased
- 2010-07-06 JP JP2012519105A patent/JP5868852B2/ja active Active
- 2010-07-06 CN CN2010800345628A patent/CN102481295A/zh active Pending
-
2011
- 2011-12-22 IL IL217143A patent/IL217143A/en active IP Right Grant
-
2012
- 2012-01-05 ZA ZA2012/00092A patent/ZA201200092B/en unknown
-
2015
- 2015-09-17 JP JP2015183914A patent/JP6204428B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2451457A1 (en) | 2012-05-16 |
| JP2016040266A (ja) | 2016-03-24 |
| ES2665305T3 (es) | 2018-04-25 |
| AU2010269849B2 (en) | 2015-07-23 |
| MX355388B (es) | 2018-04-17 |
| KR20170117211A (ko) | 2017-10-20 |
| CA2767339C (en) | 2016-05-24 |
| IL217143A0 (en) | 2012-02-29 |
| JP2012532189A (ja) | 2012-12-13 |
| CN102481295A (zh) | 2012-05-30 |
| CA2767339A1 (en) | 2011-01-13 |
| RU2563825C2 (ru) | 2015-09-20 |
| CN105688215A (zh) | 2016-06-22 |
| EP2451457B1 (en) | 2018-03-07 |
| US10688087B2 (en) | 2020-06-23 |
| IL217143A (en) | 2016-11-30 |
| KR20120052278A (ko) | 2012-05-23 |
| WO2011004325A1 (en) | 2011-01-13 |
| JP5868852B2 (ja) | 2016-02-24 |
| KR101785600B1 (ko) | 2017-10-16 |
| JP6204428B2 (ja) | 2017-09-27 |
| ZA201200092B (en) | 2012-09-26 |
| RU2012103889A (ru) | 2013-08-20 |
| MX2012000303A (es) | 2012-06-01 |
| US20120101066A1 (en) | 2012-04-26 |
| BR112012000262A2 (pt) | 2016-02-16 |
| AU2010269849A1 (en) | 2012-01-19 |
| KR101939207B1 (ko) | 2019-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2011127333A3 (en) | Compounds for treating disease, for administering, and for pharmaceutical compositions | |
| IN2012DN03182A (es) | ||
| PH12014500386A1 (en) | Combination treatment for hepatitis c | |
| MY198204A (en) | Cyclic Boronic Acid Ester Derivatives And Therapeutic Uses Thereof | |
| TN2012000416A1 (en) | Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases | |
| MX2013003634A (es) | Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales. | |
| NZ608116A (en) | Triazine-oxadiazoles | |
| IN2012DN01855A (es) | ||
| MX2011012122A (es) | Derivados de tiofeno. | |
| SG178952A1 (en) | Chemical compounds | |
| IN2015DN01119A (es) | ||
| MX350746B (es) | Derivados de ciclosporina novedosos para el tratamiento y la prevención de una infección viral. | |
| IN2012DN02139A (es) | ||
| EA201170753A1 (ru) | Налмефена гидрохлорид дигидрат | |
| WO2013028818A8 (en) | Pyrimido- pyridazinone compounds and use thereof | |
| AR047993A1 (es) | Composicion farmaceutica que comprende pimobendano | |
| MX2012013879A (es) | Derivados de hidroxipiridona, composiciones farmceuticas de los mismos y su uso terapeutico para tratar enfermedades proliferativas. | |
| TN2009000275A1 (en) | Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome | |
| WO2012135615A3 (en) | Enopeptins, uses thereof, and methods of synthesis thereto | |
| MX2013008340A (es) | Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer. | |
| EP2215054B8 (en) | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | |
| WO2011058245A8 (fr) | Nouveaux derives de mannopyranoside ayant une activite anticancereuse | |
| MX336359B (es) | Composiciones farmaceuticas y metodos teraputicos que emplean una combinacion de un compuesto complejo de manganeso y una forma compleja no de manganeso del compuesto. | |
| WO2012061012A3 (en) | 4-amino-2h-pyran-2-one analogs as anticancer agents | |
| TR200900882A2 (tr) | Tadı ve kokusu maskelenmiş, bıyoyararlanımı yüksek farmasotık bileşimler. |